Nirmatrelvir/ritonavir can be a useful COVID-19 treatment but is challenging to prescribe safely because of drug-drug interactions. This study describes our experience prescribing nirmatrelvir/ritonavir within a small interdisciplinary team with a specific focus on management of drug-drug interactions. Ascertaining and communicating modifications of concomitant medications is a key safety element.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259131 | PMC |
| http://dx.doi.org/10.1093/ofid/ofae283 | DOI Listing |
Publication Analysis
Top Keywords
prescribing nirmatrelvir/ritonavir
8
drug-drug interactions
8
telemedicine prescribing
4
nirmatrelvir/ritonavir safety
4
safety logistics
4
logistics challenges
4
challenges nirmatrelvir/ritonavir
4
nirmatrelvir/ritonavir covid-19
4
covid-19 treatment
4
treatment challenging
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!